GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Merck & Co MRK · USD

Health Care · Pharmaceuticals · US listing · 🇺🇸 United States

S&P 500Dow Jones

Compare

148.76

+1.38%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Merck & Co annual report

Filed with the US Securities and Exchange Commission

10-K

The latest annual report covers the year to 31 Dec 2025, filed on 24 Feb 2026.

Read the 10-K on SEC.gov ↗

Five-year highlights

In USD.

FY2025FY2024FY2023FY2022FY2021
Revenue$64.93bn$64.17bn$60.12bn$59.28bn$48.70bn
Operating income$23.49bn$20.22bn$2.95bn$18.28bn$13.97bn
Net income$18.25bn$17.12bn$365.0m$14.52bn$13.05bn
Free cash flow$12.36bn$18.10bn$9.14bn$14.71bn$9.66bn
Total assets$136.87bn$117.11bn$106.67bn$109.16bn$105.69bn
Shareholders' equity$52.61bn$46.31bn$37.58bn$45.99bn$38.18bn

Revenue by business

Year to 31 Dec 2017

  • Keytruda $2.31bn · 5.8%
  • Gardasil/Gardasil 9 $2.31bn · 5.8%
  • Janumet $2.16bn · 5.4%
  • Januvia $2.15bn · 5.4%
  • ProQuad/M-M-R II/Varivax $1.68bn · 4.2%
  • Zepatier $1.66bn · 4.1%
  • Other pharmaceutical $1.25bn · 3.1%
  • Remicade $837.0m · 2.1%
  • Pneumovax 23 $821.0m · 2.0%
  • Vytorin $751.0m · 1.9%

Revenue by region

Year to 31 Dec 2025

  • United States $36.51bn · 56.2%
  • Int’l $28.50bn · 43.8%
  • Europe, Middle East and Africa $14.58bn · 22.4%
  • Latin America $3.41bn · 5.2%
  • Asia Pacific (other than Japan and China) $2.98bn · 4.6%
  • Other $2.88bn · 4.4%
  • Japan $2.71bn · 4.2%
  • China $1.94bn · 3.0%

Filings

Newest first, from SEC EDGAR

Sources and methodology

Data on this tab
SEC EDGAR and our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.